Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome.
Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome.
神經基因股價下跌。該公司宣佈，2隊第一位患者接受了高劑量NGN-401基因療法，用於治療丹病綜合症女性兒童患者的1/2期試驗。
Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome.
神經基因股價下跌。該公司宣佈，2隊第一位患者接受了高劑量NGN-401基因療法，用於治療丹病綜合症女性兒童患者的1/2期試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。